47 results about "PROTHROMBIN COMPLEX" patented technology

The invention relates to a production method for adsorbing a human complex from plasma by a fixed bed column chromatography technique, which comprises the following steps: (1) cryoprecipitation plasma removal: filtering by using a cellulose deep filter plate which is cleaned by an EDTA (ethylene diamine tetraacetic acid) solution and a sodium citrate solution; (2) filtering the plasma subjected to deep filtration through a 0.2 mu m filter element membrane while fixed bed loading; (3) balancing 2-5 column volumes in a fixed bed chromatographic column filled with anion exchange gel Capto DEAE by using a buffer solution A at the plasma loading flow rate of 60-120 cm/hour, washing the chromatographic column with a buffer solution B, and eluting the chromatographic column with a buffer solution C to obtain a PCC (prothrombin complex concentrate) product. When the calculation is based on coagulation factor IX, the yield of the PCC can reach 75-90%, and the specific activity can reach 5.5 IU/mg above.

The invention relates to a preparation process of a human prothrombin compound, belonging to the field of biological pharmacy. The preparation process comprises the following steps of: absorbing blood plasma, washing, eluting and clarifying by filtration; inactivating viruses by using the S/D (Solvent/Detergent) method; purifying by absorption; subpackaging; freeze-drying; and inactivating viruses by the dry heat method. The human prothrombin compound is directly absorbed from blood plasma by using gel, only the gel chromatography technology is used in the entire extraction process, so that the production steps are simplified, the pollution of various factors on the production process of the product is reduced, meanwhile, the yield of the product is increased by 25-30%. In addition, the S/D method is used for removing lipid-enveloped viruses and the dry heat method is used for removing non lipid-enveloped viruses in the production process, and the safety of clinic medication is obviously increased through the two virus inactivation steps.

The invention relates to a method for producing a human prothrombin complex. The method is characterized in that the following steps of direct separation and extraction from blood plasma, virus inactivation, refining and secondary virus inactivation are adopted to obtain finished human prothrombin complex. As the method adopts the step of direct separation and extraction from the blood plasma, the separation condition is mild, the batch-to-batch difference of the products is small, the blood coagulation factor activity is stable, the yield rate is high, and the activation phenomenon basicallydoes not exist. The virus inactivation process adopts a method of combining an S/D (organic solvent/detergent) method and a dry and thermal activation method and fully ensures that the virus safety of the human prothrombin complex.

A process for preparing freeze dried human thrombinogen compound includes dissolving FIII deposit, low-temp centrifugal separation, filtering, gel adsorption, washing, eluting gel, superfiltering, concentrating, S/D deactivation of virus, secondary gel adsorption, washing, eluting gel, superfiltering, dialysis, removing bacteria by miniporous membrane, filtering and freeze drying. It features that said compound is deactivated in boiling water bath at 98-100 deg.C for 30 min. It has high content (2010/ml) of factor IX and high specific activity of factor IC (>0.610/ag).

The invention discloses a method for preparing a human prothrombin complex from plasma. The method comprises: directly adsorbing the human prothrombin complex from the plasma by using DEAE A-50 gel, filling the adsorbed A-50 gel into a chromatographic column of a fixed bed, pumping eluant into the filled chromatographic column by using a peristaltic pump for online washing and elution, performing S/D inactivation on the eluant, and performing secondary chromatographic purification by using the chromatographic column of the fixed bed to obtain a high-purity human prothrombin complex product. According to the method, elution flow and speed can be accurately controlled by online elution after filling the gel into the column, the problems of contamination, cross contamination, gel leakage and the like caused by an open operation are reduced, an obtained product is high in purity, an IX factor titer can exceed 27IU/ml, and the IX factor specific activity exceeds 0.8IU/mg protein. Meanwhile, a self-flushing type filter with a pressure difference controller and an automatic solid matter stripping system is adopted, so the pressure difference in the whole filtering process is stable and controllable, gel particles can be well protected, broken colloidal particles flowing into a plasma tank in the filtering process are remarkably reduced, and gel losses in a production process can be reduced by above 20%.

The invention relates to the field of bio-pharmaceutical technology, in particular to a technical method for improving stable F VII yield rate of human thrombogen complex. The following procedures are included: freshly freezing blood plasma of a healthy person at a low temperature; removing cryoprecipitate; carrying out clarification filtration; adjusting ionic strength; carrying out gel absorption; carrying out wash and elution; carrying out ultrafiltration; killing S/D virus; carrying out gel absorption; carrying out wash and elution; carrying out ultrafiltration; carrying out aseptic filtration and subpackage; carrying out freeze-drying; and carrying out hot-air sterilization.

The invention relates to a method for absorbing and separating a human prothrombin complex by utilizing an expansion bed, comprising the following steps: (a) separating cryoprecitation from melted refrigerated plasma by using a refrigeration type continuous flow centrifuge, and collecting supernate as a raw material; (b) carrying out stable expansion on an expansion bed by using a buffer solution A, wherein the buffer solution A is 0.05mol/L1tris-citric acid with the PH value of 7.0; (c) rapidly switching into a feed solution after the expansion bed is in stable balance, stopping feeding and rapidly switching into the buffer solution A when breakthrough points reaches 5-10%, and washing in an expanded mode; and (d) switching into buffer solutions of 0.4mol/L NaCl and 1.6mol/L NaCl after washing, carrying out gradient elution in a stationary bed mode, and collecting the protein elution peak of the buffer solution of 1.6mol/L NaCl to obtain a prothrombin complex crude product.

The invention belongs to the technical fields of bio-pharmaceuticals and blood products, and particularly relates to a preparation method of a human thrombinogen compound. According to the human thrombinogen compound prepared by the method, an excellent production process is obtained by improving and researching adsorbing balance liquid, subsequent washing liquid and eluent and a freeze-drying process, four blood coagulation factors that the PCC product contain have high active ratio, the yield of each component is high, the IX specific activity is up to 3.13 IU/mg, the specific activity is higher than that of the pharmacopeia standard, the thrombosis probability is effectively reduced and activation of the blood coagulation factors is reduced.

The invention relates to the field of medicinal biotechnology, and in particular to a high-purity prothrombin complex product stabilizer capable of effectively preventing the inactivation of a blood coagulation factor IX with a main effect and blood coagulation factors II, VII and X in a product in a freeze-drying process, wherein the specific activity of each of four blood coagulation factors II, VII, IX and X is greater than or equal to 3.5IU/mg protein. The stabilizer provided by the invention contains arginine or/and trehalose or/and histidine or/and glycine. The tests show that so long as the high-purity prothrombin complex contains 0.1-10% of arginine or/and 0.1-10% of trehalose or/and 0.1-10% of histidine, the activity of the blood coagulation factor IX and the activity of the blood coagulation factors II, VII and X can be effectively protected in the freeze-drying process. Thus, the stabilizer provided by the invention can be applied to the freeze-drying process of the high-purity prothrombin complex.

The invention provides a process for purifying a prothrombin compound. The process comprises the following steps: subjecting qualified detected plasma of a healthy person to centrifugation for removal of sediments so as to a raw plasma material; subjecting the raw plasma material to adsorption with DEAE-Sephadex A-50 gel and carrying out washing and elution so as to obtain crude extract of the prothrombin compound; and subjecting the crude extract of the prothrombin compound to further adsorption by using Capto DEAE gel column chromatography and carrying out washing and elution so as to obtain the liquid prothrombin compound. According to the invention, the prothrombin compound is prepared through two-step operations via the DEAE-Sephadex A-50 gel and Capto DEAE gel; and under the designed process conditions, the prepared prothrombin compound has a purity far higher than the purity of a prothrombin compound product prepared by using a traditional process, and blood coagulation factors II, IX and X are good in equalization.

The invention relates to the field of blood products and particularly relates to a preparation method of human thrombin. The invention provides a preparation method of human thrombin, which comprises the following steps: 1) performing redissolution and virus inactivation of a component III obtained by Cohn fraction of human plasma; and purifying the obtained liquid through anion exchange resin to obtain prothrombin complex eluent; 2) adding calcium ions into the eluent obtained in the step 1), and incubating until the prothrombin is effectively activated; 3) separating and purifying the liquid obtained in the step 2) through cation exchange resin; and 4) performing nano membrane filtration of the liquid obtained in the step 3) to obtain a finished product of human thrombin. In the preparation method provided by the invention, by adopting the thrombin product of the technology market, the human thrombin has high vigor, high yield and good long-term stability, meets the requirements on safety and effectiveness of clinical application and is of relatively obvious economic value and practical significance.

The invention discloses a method for extracting equilibrium liquid in a human prothrombin compound and extracting the human prothrombin compound. The equilibrium liquid for extracting the human prothrombin compound contains 0.10mol/L to 0.15mol/L of sodium chloride and 0.01mol/L to 0.02mol/L of sodium citrate, and the pH value of the equilibrium liquid is 6.8 to 7.2. By utilizing the equilibrium liquid, the human prothrombin compound can be effectively extracted, the yield and purity are relatively high, and particularly the yield of a blood coagulation factor VII (F VII) is relatively high. In addition, the stability of the obtained human prothrombin compound is relatively good.

The invention discloses a method for detecting anticoagulant capacity of a human prothrombin complex. The method comprises the following steps: (1) taking the human prothrombin complex, diluting until a blood coagulation factor IX is 0.8-1.3IU/ml, adding a human prothrombin solution with the isovolumetric concentration being 4-6IU/ml, mixing evenly, and standing at room temperature for 1-2 minutes; (2) adding a thrombin chromogenic substrate solution which is isovolumetric to the human prothrombin solution, mixing evenly, and incubating at 22-28 DEG C for 4-6 minutes, wherein the concentration of the chromogenic substrate solution is 0.5-0.7mg/ml; (3) determining a light absorption value at the wavelength of 405nm, and determining once 30-50 seconds for 5-8 times in all; and (4) drawing the time changing trend along with the light absorption value by taking the determined light absorption value as a longitudinal coordinate (y) and time (s) as a cross coordinate (x), building a linear equation y=kx+a, wherein k is slope, and calculating the value of 1/k. The method for detecting the anticoagulant capacity of the human prothrombin complex is simple and convenient to operate and good in repeatability; the comprehensive anticoagulant ability of the PCCs product can be quantitatively detected; and the safety of the PCCs product can be evaluated.

The invention discloses a method for simultaneously separating and purifying coagulation factors IX, X and VII from human plasma, which comprises the following steps: performing centrifugal impurity removal, gel adsorption and ultrafiltration concentration to prepare a prothrombin compound; separating the coagulation factors VII and a mixed solution containing IX and II through an anion exchange resin column; separating the coagulation factor II and IX from the mixed solution containing IX and II by affinity chromatography. According to the method, by combining anion exchange chromatography with heparin affinity chromatography, the separation and preparation of three coagulation factors II, VII and IX at the same time can be achieved; the method has the advantages of high raw material utilization, simple operation and short time consumption; meanwhile, by detecting the electric signals in the chromatography process, the corresponding coagulation factors are accurately collected, the purity of the coagulation factors is effectively improved, and the economic benefit is improved.

The invention relates to a stabilizing agent for preventing blood clotting factor reactive loss for prothrombin composite or blood clotting factor IX preparation during virus animatum eradication by dry heat, wherein the stabilizing agent is sucrose or / and arginine or its salt, it also can contain one or more of the conventional glycine, NaCl, citric acid trisodium and hamocura.

The invention relates to the field of medicament, in particular to an in-vitro microplate-based screening method of tissue factor (TF) pathway inhibitors, and is characterized in that the invention comprises the following steps: incubating cells and the medicament to be measured together; getting cell lysis solution after freeze thaw, blowing and beating; putting the cell lysis solution on the microplate for incubation; adding human prothrombin complex solution for incubation; adding chromogenic substrate solution in the reactant liquor for incubation; measuring the value of absorbance with a micro-plate reader of 405nm. The invention also discloses some tissue factor pathway inhibitors screened out by using the method, such as hydroxygenkwanin, ruscogenin, quercetinic acid, ginsenoside Rb1, ginsenoside or diosgenin and so on.

The invention discloses a dry-heat treatment stabilizer for a human prothrombin complex, and further provides application of the dry-heat treatment stabilizer and the human prothrombin complex prepared through the dry-heat treatment stabilizer. The dry-heat treatment stabilizer can not only effectively keep the activity of the human prothrombin complex but also ensure the virus inactivation effect of dry-heat treatment, is simple in formula and low in preparation cost and has the good industrial application prospect.

The invention relates to an adsorption and separation device for human prothrombin complex, belonging to the technical fields of biochemical industry and biopharmaceuticals. The present invention includes a tank body and a stirring part, the tank body is provided with a buffer distribution pipe and a feed pipe, and the buffer liquid distribution pipe and the feed pipe extend from the top of the tank body to Inside the tank, the top of the tank is also provided with a manhole; the bottom of the tank is provided with an openable tank bottom, the top of the tank bottom is provided with a filter plate, and the bottom of the tank bottom is A tank bottom valve is provided. The adsorption and separation device for human prothrombin complex of the present invention has comprehensively improved the adsorption tank, and realizes that the adsorption and separation of human prothrombin complex can be completed in the same device.

The invention discloses a method for effectively inactivating parvovirus (PPV) in a prothrombin complex. The method comprises the following steps: lyophilizing an S/D inactivated parvovirus in prothrombin complex preparation, carrying out dry-heat treatment for 2-10 hours at 80 DEG C and for 30-120 hours at 100 DEG C. The invention further discloses a prothrombin complex preparation prepared by the method. The inactivating method can be used for effectively inactivating PPV over 4log; the prothrombin complex preparation prepared by the method has high virus safety and good long-time stability, is qualified in full-inspections after being placed for 3 years at 2-8 DEG C, and has an FIX recovery rate of over 90 percent; and the II, VII, IX and X blood coagulation factors are not remarkably lost, and an excellent proportion is maintained. Furthermore, the preparation method has low cost which is lower than that of traditional 80-DEG C 72-hour dry-heat inactivation.

The invention discloses a process for preparing a human prothrombin complex concentrate by adopting a flow adsorption method. The process is characterized in that a plurality of cylindrical containerswith stirrers are connected in series to form a natural flowing way; gels which are balanced in advance are placed in the various containers; a certain batch of to-be-processed blood plasma is storedabove the first container; the gels are injected quantitatively firstly in the first container, then the gels are stirred and adsorbed for a unit time, and the adsorbed blood plasma is discharged into the second container at a certain flow speed; simultaneously, other to-be-processed blood plasma flows into a first adsorption tank at the same flow speed, so that dynamic balance of the blood plasma quantity in the first container is kept, and at this time, adsorption and separation of the blood plasma in the first container are carried out simultaneously; by analogy, after the all blood plasmapasses through, outlets of the various containers are closed, and washing and elution on the gels are carried out. The blood plasma quantity is not limited by the volume of the containers, the process is easily controlled, an FIX activety recycling ratio is higher, and the risks of leakage of the gels and crossed pollution are avoided.